

as well as summaries of the meeting and a roster of committee members may be obtained from James Scanlon, NCVHS Executive Staff Director, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 444-D, Humphrey Building, 200 Independence Avenue S.W., Washington, D.C. 20201, telephone (202) 690-7100, or Marjorie S. Greenberg, Acting Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone (301) 436-7050. Information also is available on the NCVHS homepage: <http://aspe.os.dhhs.gov/ncvhs/index.htm>.

Dated: January 2, 1997.

James Scanlon,

Director, Division of Data Policy, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 97-434 Filed 1-8-97; 8:45 am]

BILLING CODE 4151-04-M

Centers for Disease Control and Prevention

Epidemiology Program Office, Office of the Director, Centers for Disease Control and Prevention (CDC), Notice of Meeting

Name: Guide to Community Preventive Services Task Force Meeting.

Times and Dates: 8:30 a.m.-5 p.m., January 27, 1997; 8:30 a.m.-5 p.m., January 28, 1997.

Place: Terrace Garden Inn, 3405 Lenox Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by the space available.

Purpose: The mission of the Task Force is to develop and publish a Guide to Community Preventive Services, which is based on the best available scientific evidence and current expertise regarding essential public health services and what works in the delivery of those services. The primary purpose of this second meeting is to continue in the development of a shared vision for the Guide; review and assess the methods used in the initial development of the first two chapters; and to select additional topics to be included in the Guide.

Matters to be Discussed: Agenda items include the definition of "community" for the Guide; defining target audiences for the Guide; process for selection of topics to be included in the Guide; updates on current chapters in progress: the prevention of (a) motor vehicle injuries and (b) vaccine preventable diseases; and selection of new topics for upcoming chapters.

Agenda items are subject to change as priorities dictate.

FOR ADDITIONAL INFORMATION CONTACT: Marguerite Pappaioanou, Chief, Community Preventive Service Guide Development Activity, Division of Prevention Research and Analytic Methods, Epidemiology Program Office, CDC, 1600 Clifton Road, NE, M/S D-01, Atlanta, Georgia 30333, telephone 404/639-4301.

Persons wishing to reserve a space for this meeting should call 404/639-4311 by close of business on January 21, 1997.

Dated: January 3, 1997.

Joseph E. Salter

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-467 Filed 1-8-97; 8:45 am]

BILLING CODE 4163-18-P

National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC); Notice of Meeting

Name: Translating Advances in Genetics into Public Health Action.

Times and Dates: 10 a.m.-5:30 p.m., January 27, 1997; 8 a.m.-3 p.m., January 28, 1997.

Place: Terrace Garden Hotel, 3405 Lenox Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by the space available.

Purpose: CDC has established a Task Force on Genetics in Disease Prevention to: (1) develop a strategic plan for CDC-wide genetics programs, (2) coordinate and support program efforts, and (3) convene constituents and consultants for their individual advice on strategic planning, priorities for CDC activities, and policy development. This Task Force was formed in October, and is in the process of collecting and summarizing information about CDC efforts related to genetics that will be used during strategic planning.

This meeting will enable invited participants (individuals from academia, public health, professional organizations, consumer groups, and industry) to provide input and discuss strategic planning issues and needs associated with the translation of advances in genetics into public health action. Information gained from this meeting will be considered, along with that previously received, in drafting strategic planning documents. These documents will then be distributed for further comment.

Matters to be Discussed: Agenda items include discussions on population-based assessment functions, development of public health policies and guidelines, quality assurance and prevention effectiveness functions, and needs for professional

education and information dissemination efforts.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Dometa Williams, Genetics Task Force, NCEH, CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30341, telephone 770/488-7120, FAX 770/488-7197.

Dated: January 3, 1997.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-460 Filed 1-8-97; 8:45 am]

BILLING CODE 4163-18-P

Food and Drug Administration

[Docket No. 97N-0003]

Hoffman-LaRoche, Inc., et al.; Withdrawal of Approval of 11 New Drug Applications, 1 Abbreviated Antibiotic Application, and 20 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 11 new drug applications (NDA's), 1 abbreviated antibiotic application (AADA), and 20 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: February 10, 1997.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1046.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
NDA 6-525	Gantrisin (sulfisoxazole) Tablets	Hoffman-La Roche, Inc., 340 Kingsland St., Bldg. 719-4, Nutley, NJ 07110.
NDA 12-486	Taractan (chlorprothixene) Tablets	Do.
NDA 12-772	Haldrone (paramethasone acetate) Tablets	Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.